Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the Week Suggested by the BPDCN International Registry – Astghik Voskanyan
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has emerged as a distinct hematologic malignancy due to its unique clinical presentation, including violaceous skin lesions, bone marrow/blood involvement, lymph node invasion, and extramedullary organ involvement, notably in the CNS. Historically affecting older males (median age ≥70, 5:1 male predominance), BPDCN is now recognized in younger, female, and CNS-positive cases, reflecting advances in diagnosis and international collaboration. Since the approval of tagraxofusp, a CD123-targeted therapy, BPDCN treatment has improved, particularly in frontline settings. The field is evolving with better molecular understanding, new potential therapeutic targets, combination therapies, stem cell transplant strategies, and ongoing clinical trials.”
Author: Naveen Pemmaraju.
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.
Other posts featuring Immune Oncology Research Institute on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023